From Barchart: 2025-02-05 02:00:04

In the medical device industry, Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is set to report an EPS of $2.30 for Q4 2024, a 4.6% increase year-over-year. Revenue is expected to hit $2.01 billion, up by 3.7% from last year. Despite a slight EPS estimate revision, Zimmer Biomet has a history of beating earnings expectations.

Zimmer Biomet specializes in musculoskeletal healthcare, offering orthopedic reconstructive products like knee and hip implants. Competing with major players like Stryker Corporation and Johnson & Johnson, the company is a key player in the orthopedic market.

Analysts anticipate Zimmer Biomet’s Q4 2024 earnings to be $2.30 per share, representing a 4.6% growth from the previous year. Revenue is expected to reach $2.01 billion, showing a 3.7% increase. These figures indicate positive financial performance for the company.

Despite a slight downward revision in EPS estimates, Zimmer Biomet has a track record of surpassing earnings expectations in three of the last four quarters. The company’s Hips business is expected to drive growth, thanks to navigation solutions in direct anterior stems and surgical impactors.



Read more at Barchart:: Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Earnings P…